Shubham Pant: Phase 1 AMPLIFY-201 trial

Shubham Pant, Professor, Department of Gastrointestinal (GI) Medical Oncology and Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, shared on LinkedIn:

“On behalf of my Co-investigators: Excited to finally see in print. Phase 1 AMPLIFY-201 trial.

– Eli-002 vaccine for G12D and G12R mutant KRAS
– 25 patients with Pancreatic and Colorectal cancer s/p locoregional therapy and no evidence of disease on imaging
– Tumor biomarker responses in 84% of patients
– Efficacy Correlated with strength of T cell response: Median RFS not reached for above median T cell responders vs. 4.01 mo. for below median T cell responders (HR= 0.14; p=0.016)
– Well tolerated. Main AE injection site reaction. No DLT’s
High-five to an Amazing group of co-investigators.
Another step towards the goal.

Visit the article website

Source: Shubham Pant/LinkedIn